公开(公告)号：US11136365B2

公开(公告)日：2021-10-05

申请号：US16196823

申请日：2018-11-20

Applicant: Genentech, Inc.

Inventor： Justin Scheer ,  Wenjun Ouyang ,  Richard Vandlen ,  Philip E. Hass ,  Eric Gary Stefanich ,  Ganesh A. Kolumam ,  Xiaoting Wang ,  Jed Ross ,  Nicholas Van Bruggen

IPC: C07K14/54 ,  C07K16/28 ,  A61K38/20 ,  A61K47/38 ,  A61K38/00

Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.

公开(公告)号：US10087227B2

公开(公告)日：2018-10-02

申请号：US15369236

申请日：2016-12-05

Applicant: Genentech, Inc.

Inventor： Justin Scheer ,  Wenjun Ouyang ,  Richard Vandlen ,  Philip E. Hass ,  Eric Gary Stefanich ,  Xiaoting Wang

IPC: C12N15/25 ,  C07K14/54

Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.

公开(公告)号：US09884126B2

公开(公告)日：2018-02-06

申请号：US14284619

申请日：2014-05-22

Applicant: Genentech, Inc.

Inventor： Eric J. Brown ,  John Flygare ,  Wouter Hazenbos ,  Sophie M. Lehar ,  Sanjeev Mariathasan ,  John Hiroshi Morisaki ,  Thomas H. Pillow ,  Leanna Staben ,  Richard Vandlen ,  Klaus Koefoed ,  Magnus Strandh ,  Peter S. Andersen

IPC: A61K47/48 ,  C07K16/12 ,  A61K31/395 ,  A61K31/4375 ,  A61K31/439 ,  A61K31/4436 ,  A61K31/4709 ,  A61K31/7048 ,  A61K31/7056 ,  A61K38/12

CPC classification number: A61K47/6849 ,  A61K31/395 ,  A61K31/4375 ,  A61K31/439 ,  A61K31/4436 ,  A61K31/4709 ,  A61K31/7048 ,  A61K31/7056 ,  A61K38/12 ,  A61K47/6801 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6835 ,  A61K47/6851 ,  C07K16/1271 ,  C07K2317/21 ,  C07K2317/522 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/624 ,  C07K2317/92

Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.

公开(公告)号：US20150017188A1

公开(公告)日：2015-01-15

申请号：US14152287

申请日：2014-01-10

Applicant: Genentech, Inc.

Inventor： Charles W. Eigenbrot, JR. ,  Jagath Reddy Junutula ,  Henry Lowman ,  Helga E. Raab ,  Richard Vandlen

IPC: A61K47/48 ,  A61K45/06

CPC classification number: A61K47/6803 ,  A01K2267/0331 ,  A61K45/06 ,  A61K47/6817 ,  A61K47/6851 ,  A61K47/6889 ,  C07K16/00 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/51 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/624

Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p  I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.

Abstract translation: 通过用非交联的高反应性半胱氨酸氨基酸替代亲本抗体的一个或多个氨基酸来设计抗体。 抗体片段也可以用一个或多个半胱氨酸氨基酸进行工程化以形成半胱氨酸改造的抗体片段（ThioFab）。 提供了设计，制备，筛选和选择半胱氨酸改造的抗体的方法。 任选与白蛋白结合肽（ABP）序列的半胱氨酸改造的抗体（Ab）通过接头（L）与一个或多个药物部分（D）缀合，形成具有式I：Ab- （LD）p I，其中p为1至4.披露了半胱氨酸改造的抗体药物化合物和组合物的诊断和治疗用途。

公开(公告)号：US20140323706A1

公开(公告)日：2014-10-30

申请号：US13850095

申请日：2013-03-25

Applicant: GENENTECH, INC.

Inventor： Jian Chen ,  Ellen Filvaroff ,  Sherman Fong ,  Audrey Goddard ,  Paul Godowski ,  Christopher Grimaldi ,  Austin Gurney ,  Hanzhong Li ,  Kenneth Hillan ,  Daniel Tumas ,  Menno VanLookeren ,  Richard Vandlen ,  Colin Watanabe ,  P. Mickey Williams ,  William I. Wood ,  Daniel Yansura

IPC: C07K14/705

CPC classification number: C07K14/705 ,  A61K38/00 ,  C07K14/54 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57423 ,  G01N2500/04

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract translation: 本发明涉及新型多肽和编码那些多肽的核酸分子。 本文还提供了包含那些核酸序列的载体和宿主细胞，包含与异源多肽序列融合的本发明的多肽的嵌合多肽分子，与本发明的多肽结合的抗体以及本发明的多肽的制备方法 发明。